BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37326221)

  • 1. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
    Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
    Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
    Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
    Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
    Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
    Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert opinion on sonidegib efficacy, safety and tolerability.
    Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
    [No Abstract]   [Full Text] [Related]  

  • 7. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
    Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.
    Lear JT; Morris LM; Ness DB; Lewis LD
    Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
    Collier NJ; Ali FR; Lear JT
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
    Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
    Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?
    Zhu H; Lewis DJ
    Expert Opin Pharmacother; 2022 Apr; 23(6):739-740. PubMed ID: 35258366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
    Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
    Actas Dermosifiliogr; 2023; 114(7):T565-T571. PubMed ID: 37302483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
    Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
    Actas Dermosifiliogr; 2023; 114(7):565-571. PubMed ID: 37088285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
    Xie P; Lefrançois P
    J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.